Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to {beta}-blocker therapy in hypertension

Conclusions The ADRB1 1165G > C gene polymorphism and β-blocker treatment duration are independent factors associated with β-blocker treatment outcome. These findings suggest that the selection of antihypertensive therapy should take into consideration the patient’s genotype.

http://imr.sagepub.com/cgi/content/abstract/43/3/424?rss=1

Source: Journal of International Medical Research - May 18, 2015 Category: Research Authors: Wu, D., Li, G., Deng, M., Song, W., Huang, X., Guo, X., Wu, Z., Wu, S., Xu, J. Tags: Clinical Reports Source Type: research